Business Insider
My Markets Watchlist
Markets Stocks

CSL Ltd. Stock , CMXHF

242.96 AUD -3.26 -1.32%
02:22:15 AM EDT 6/5/2025 AUSX
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


CSL Stock Snapshot

76.13 B
Market Cap in USD
484.21 M
Number of Shares
484.21 M
Total Number of Shares
3.97
Dividend in AUD
1.35
Dividend Yield
35.37
P/E Ratio
99.94
Free Float in %
8.35
EPS in AUD
53.80
Book Value per Share in AUD
8.69
Cash Flow per Share in AUD

CSL Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

CSL Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 15,667 16,636 17,824 18,821 19,535
Dividend 2.90 3.16 3.62 4.08 4.34
Dividend Yield (in %) 1.91 % 2.08 % 2.39 % 2.69 % 2.86 %
EPS 6.47 7.34 8.49 9.34 10.21
P/E Ratio 23.43 20.63 17.84 16.22 14.84
EBIT 4,484 5,004 5,652 6,084 6,413
EBITDA 5,239 5,783 6,451 6,898 7,241
Net Profit 3,159 3,578 4,093 4,494 4,874
Net Profit Adjusted 3,172 3,544 4,017 4,535 -
Pre-Tax Profit 4,058 4,614 5,313 5,802 -
Pre-Tax Profit Reported 4,059 4,533 5,245 5,802 -
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 6.32 7.00 8.14 9.41 10.91
Gross Income 8,563 9,377 10,244 11,513 -
Cash Flow from Investing -455 -561 -440 -1,204 -
Cash Flow from Operations 3,821 4,227 4,796 5,085 -
Cash Flow from Financing -2,041 -1,913 -2,222 -1,988 -
Cash Flow per Share 7.18 9.20 9.90 11.04 11.88
Free Cash Flow 2,473 3,205 3,724 4,409 -
Free Cash Flow per Share 4.61 6.64 7.46 9.06 -
Book Value per Share 39.63 43.41 48.01 53.03 59.42
Net Debt 9,340 7,853 6,218 4,701 1,414
Research & Development Exp. 1,468 1,632 1,735 - -
Capital Expenditure 776 869 955 1,204 -
Selling, General & Admin. Exp. 2,693 2,895 2,982 - -
Shareholder’s Equity 20,375 22,116 24,294 27,843 -
Total Assets 38,301 40,030 42,057 45,948 -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 06/30/25 		Next Year
ending 06/30/26
Earnings Estimates
No. of Analysts - - - 11 11
Average Estimate - - - 6.465 USD 7.344 USD
Year Ago - - - 8.347 USD -
Publish Date - - - 10/28/2025 -
Revenue Estimates
No. of Analysts - - - 11 10
Average Estimate - - - 15,667 USD 16,636 USD
Year Ago - - - 22,418 USD -
Publish Date - - - 10/28/2025 -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. AUD

2024 2023 2022 2021 2020 2019 2018
Sales 22,417.63 19,585.29 14,469.43 13,761.48 13,575.28 11,899.41 10,131.64
Change of sales in % 14.46 35.36 5.14 1.37 14.08 17.45 10.37
Gross profit on sales 10,912.76 9,465.58 7,676.18 7,644.94 7,613.07 6,497.07 5,499.20
Gross profit on sales change in % 15.29 23.31 0.41 0.42 17.18 18.15 17.67
Operating income 5,649.43 4,360.38 3,941.86 4,136.10 3,977.34 3,435.63 3,009.40
Operating income change in % 29.56 10.62 -4.70 3.99 15.77 14.16 28.30
Income before tax 5,150.41 3,958.98 3,832.92 3,972.28 3,837.71 3,273.56 2,944.09
Income before tax change in % 30.09 3.29 -3.51 3.51 17.23 11.19 31.39
Income after tax 4,031.82 3,336.07 3,109.11 3,183.88 3,136.31 2,682.92 2,231.30
Income after tax change in % 20.86 7.30 -2.35 1.52 16.90 20.24 25.82

Balance Sheet in Mio. AUD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 27,882.01 27,654.17 20,022.54 13,021.11 12,980.54 10,064.98 9,060.84
Long-term liabilities per share 42.36 42.98 20.11 19.42 21.61 15.22 14.19
Equity 29,049.94 26,779.84 21,199.01 11,163.90 9,480.61 7,483.15 5,521.96
Equity change in % 9.63 11.87 89.89 17.76 26.69 35.52 33.88
Balance sheet total 56,931.95 54,434.01 41,221.55 24,185.01 22,461.15 17,548.13 14,582.80
Balance sheet total change in % 4.59 32.05 70.44 7.67 28.00 20.33 22.61

Key Data in AUD

2024 2023 2022 2021 2020 2019 2018
Sales per share 46.20 40.47 30.78 30.17 29.80 26.21 22.32
P/E ratio (year end quote, basic EPS) 35.37 40.09 40.57 40.74 41.53 36.30 39.05
P/E ratio (year end quote, diluted EPS) 35.53 40.23 40.68 40.86 41.69 36.38 39.18
Dividend yield in % 1.35 1.31 1.18 1.03 1.02 1.24 1.19
Equity ratio in % 51.03 49.20 51.43 46.16 42.21 42.64 37.87
Debt ratio in % 48.97 50.80 48.57 53.84 57.79 57.36 62.13

CSL Dividend Calendar

Date Name Dividend *yield Currency
2024 CSL Ltd. 3.97 1.35 AUD
2023 CSL Ltd. 3.63 1.31 AUD
2022 CSL Ltd. 3.18 1.18 AUD
2021 CSL Ltd. 2.94 1.03 AUD
2020 CSL Ltd. 2.94 1.02 AUD
2019 CSL Ltd. 2.66 1.24 AUD
2018 CSL Ltd. 2.28 1.19 AUD
2017 CSL Ltd. 1.75 1.27 AUD
2016 CSL Ltd. 1.70 1.52 AUD
2015 CSL Ltd. 1.64 1.90 AUD
2014 CSL Ltd. 1.24 1.86 AUD
2013 CSL Ltd. 1.06 1.72 AUD
2012 CSL Ltd. 0.83 2.11 AUD
2011 CSL Ltd. 0.80 2.42 AUD
2010 CSL Ltd. 0.80 2.46 AUD
2009 CSL Ltd. 0.70 2.18 AUD
*Yield of the Respective Date

CSL Calendar

Event Estimate Info Date
Earnings Report - Q4 2025 Earnings Release 08/19/2025
Annual General Meeting 6.465 USD Annual General Meeting 10/28/2025
Earnings Report - Q2 2026 Earnings Release 02/18/2026
Earnings Report - Q4 2026 Earnings Release 08/18/2026
Earnings Report - Q2 2027 Earnings Release 02/17/2027
Earnings Report - Q4 2027 Earnings Release 08/17/2027

CSL Past Events

Event Actual EPS Info Date
Earnings Report - Q2 2025 Earnings Release 02/11/2025
Annual General Meeting 8.348 AUD Annual General Meeting 10/28/2024
Earnings Report - Q4 2024 Earnings Release 08/12/2024
Earnings Report - Q2 2024 Earnings Release 02/12/2024
Annual General Meeting 6.764 AUD Annual General Meeting 10/10/2023
Earnings Report - Q4 2023 Earnings Release 08/14/2023
Earnings Report - Q2 2023 Earnings Release 02/13/2023
Annual General Meeting 6.633 AUD Annual General Meeting 10/11/2022
Earnings Report - Q4 2022 Earnings Release 08/16/2022
Earnings Report - Q2 2022 Earnings Release 02/16/2022

CSL Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia. .

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
2
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

CSL Management

Name Job
Brian Anthony McNamee Chairman
Kate Sophie Priestman Chief Corporate & External Affairs Officer
Mark Hill Chief Digital Information Officer
Paul McKenzie Chief Executive Officer, MD & Director
John Levy Chief Financial Officer
Roanne Parry Chief Human Resources Officer
Andrew Nash Chief Scientific Officer, SVP & Head-Research
Ken Lim Chief Strategy Officer & Executive Vice President
Jeffrey Alan Ball Chief Sustainability Officer
William Mezzanotte Executive VP, Head-Research & Development
Gregory Allan Boss Executive VP-Legal & Group General Counsel
Joy Carolyn Linton Executive Vice President-CSL Behring
Samantha Louise Lewis Independent Non-Executive Director
Marie McDonald Independent Non-Executive Director
Carolyn Judith Hewson Independent Non-Executive Director
Alison Mary Watkins Independent Non-Executive Director
Megan Elizabeth Clark Independent Non-Executive Director
Elaine K. Sorg Independent Non-Executive Director
Robert Andrew Cuthbertson Non-Independent Non-Executive Director
Fiona McCallum Mead Secretary & Head-Corporate Governance
Chris Cooper Vice President & Head-Investor Relations